Petkovikj, Elena

Preferred name

Petkovikj, Elena

Official Name

Petkovikj, Elena

Translated Name

Петковиќ, Елена

Alternative Name

Petkovikj, Elena

Petkovik, Elena

Petkovic, Elena

Elena Petkovikj

Петковиќ, Елена

Main Affiliation

Now showing 1 - 9 of 9

Some of the metrics are blocked by your
consent settings
Sociodemographic characteristics and thrombophilic mutations in women with in vitro fertilization failure â€“ initial results from case control study
(Institute of Public Health of the Republic of Macedonia/Scientific Foundation SPIROSKI, 2019-08-22)
;
Hristova Dimceva, Anita
;
Grubovic Rastvorceva, Rada
;
Useini, Sedula
There are many factors for in vitro fertilization (IVF) failure, and hereditary thrombophilia has been mentioned as one of them in the last few years. Thrombophilia is a condition of predisposition to thromboembolism. The aim of the study was to evaluate the sociodemographic characteristics and to examine the representation of thrombophilic mutations in women with IVF failure. Material and methods: In a retrospective-prospective case-control study we evaluated 52 women, divided in two groups. Twenty-twowomen with at least three IVF failures were included in the examined group (EG). Thirty women, age matched, who gave birth to at least one healthy child without obstetric complications were included in the control group. Presence of gene mutations for factor II Prothrombin (G20210A), factor V Leiden (FVL) and methylentetrahydrofolate reductase (MTHFR C677T) was examined in both groups. Sociodemographic data, data from personal, family and obstetric anamnesis was collected with standard questionnaire. Results: Representation of nationality in both groups roughly corresponds to the national structure in Republic of Macedonia. In both groups the most prevalent age was from 30 to 34 years (40% in the CG and 50% in the EG). According to the degree of education, homogeneity between the two groups was registered. In most of the EG, MTHFR heterozygous was 63.6% vs. 56.7% in the CG, followed by the FV Leiden heterozygous with 13.6% vs. 3.3% in the CG, MTHFR homozygous with 9.1% vs. 6.7% in CG, factor II Prothrombin (G20210A) heterozygous with 4.5% vs. 6.7 in CG. 72.7% of women in the EG and 60% in the CG had one thrombophilic mutation, and 9.1% of women in EG and 6.7% in CG had two thrombophilic mutations. 18.2% of women in EG and 33.3% in CG did not have any mutations. Conclusion: The sociodemographic profile of women with IVF failure is a woman aged between 30 and 34 years with a university degree, with at least one thrombophilic mutation. Thrombophilic mutation has not been registered in only a small percentage of women with failed IVF.</jats:p>
Some of the metrics are blocked by your
consent settings
Apheresis collection of peripheral blood stem cells in hematological patients and healthy donors - 21 years of experience
(Elsevier BV, 2021-05)
Grubovic Rastvorceva, R
;
Useini, S
;
Some of the metrics are blocked by your
consent settings
Development of Transfusion Medicine in Republic of North Macedonia
(2022)
;
;
Dejanova-Ilijevska, Violeta
;
;
Ristovska, Elena
Transfusion medicine has been successfully practiced in North Macedonia for 76 years. Since its foundation, the Transfusion Medicine Unit is constantly growing and developing through the experiences of a large number of professional medical workers who left a lasting mark and paved the way toward modern transfusion activity. The Institute for transfusion medicine of North Macedonia constantly follows the latest world achievements in the field of transfusion medicine and they invest their energy in constant education, new technologies, and appropriate practices that ensure a high level of health services for donors and patients. This manuscript presents the journey of transfusion medicine in the Republic of North Macedonia covering various topics like the History, changes in legislation over time, blood donation activity ,other services and the future directions for the field of transfusion medicine in the country.
Some of the metrics are blocked by your
consent settings
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients-An Open-Label Phase II Clinical Trial
(MDPI AG, 2022-10-09)
Grubovic Rastvorceva, Rada M
;
Useini, Sedula
;
;
;
Background: COVID-19 convalescent plasma (CCP) is an important antiviral option for selected patients with COVID-19. Materials and Methods: In this open-label, phase 2, clinical trial conducted from 30 April 2020 till 10 May 2021 in the Republic of North Macedonia, we evaluated the efficacy and safety of CCP in hospitalized patients. Treatment was with a single unit of CCP having an anti-RBD IgG concentration higher than 5 AU/mL. Results: There were 189 patients that completed the study, of which 65 (34.4%) had WHO 8-point clinical progression scale score of 3 (requiring hospital care but not oxygen support), 65 (34.4%) had a score of 4 (hospitalized and requiring supplemental oxygen by mask or nasal prongs), and 59 (31.2%) had a score of 5 (hospitalized and requiring supplemental oxygen by non-invasive ventilation or high-flow oxygen). Mean age was 57 years (range 22−94), 78.5% were males, 80.4% had elevated body mass index, and 70.9% had comorbidity. Following CCP transfusion, we observed clinical improvement with increase rates in oxygenation-free days of 32.3% and 58.5% at 24 h and seven days after CCP transfusion, a decline in WHO scores, and reduced progression to severe disease (only one patient was admitted to ICU after CCP transfusion). Mortality in the entire cohort was 11.6% (22/189). We recorded 0% mortality in WHO score 3 (0/65) and in patients that received CCP transfusion in the first seven days of disease, 4.6% mortality in WHO score 4 (3/65), and 30.5% mortality in WHO score 5 (18/59). Mortality correlated with WHO score (Chi-square 19.3, p < 0.001) and with stay in the ICU (Chi-square 55.526, p ≤ 0.001). No severe adverse events were reported. Conclusions: This study showed that early administration of CCP to patients with moderate disease was a safe and potentially effective treatment for hospitalized COVID-19 patients. The trial was registered at clinicaltrials.gov (NCT04397523).
Some of the metrics are blocked by your
consent settings
Rh D genotyping in pregnancy-present and future
(ECronicon Open Access, 2021-11-01)
;
;
Hristova Dimcheva, Anita
;
Dejanova-Ilijevska, Violeta
;
Background: The RBC’s (Red Blood Cell’s) antigen can cause alloimmunisation during pregnancy if the fetus inherited the antigen from the father that is not present in the mother. In most of the cases the RBS’s antibody are from IgG class and they cross the placental barrier, binding the Fc receptors as an active one way transport from the mother to the fetus and never cross versa. Aim: To emphasize that methods of genotyping in pregnancy improve the management of sensibilised pregnancies in high risk of HDFN easier and safer minimising the unnecessary procedure. Prove that with genotyping antenatal use of RhIG can be reduced, same as use of RhD-negative blood for transfusion. Materials and Methods: All pregnant women were tested for ABO, RhD, Rh phenotype, K and screening of alloantibodies in the first trimester of pregnancy. Pregnant women who have the DVI phenotype are typed as D-negative. Pregnant women, 50 in total, with weak expression of D, with score < 2+, including those with DEL phenotype, were tested with a panel of D monoclonal antibodies, commercial kit, or by molecular testing, for RhD variants. Results: The results that we have obtained show that 17 samples were RhD-negative and 33 samples showed results for weak D: weak D Type 1 (60,6%), Type 2 (12,2%), Type 3 (24,2%) and only 1 pregnant woman was RhD Type 4. The research also included 30 pregnant women where the RhD fetal status had been detected by non-invasive technique from the mother’s plasma, by Real time PCR method, between the 12 and 31 gestation week. Acquired results demonstrated that 12 fetuses were female, 16 were male and 3 fetuses were without specified sex. Conclusion: In our study only 3% of RhD-negative mothers needed RhIG prophylaxis, and 97% were weak D variants 1 - 3 that we can consider as RhD-positive and they didn’t need an RhIG prophylaxis, subsequently they can be transfused with RhD-positive blood. According to the results, we provide RhIG antenatal prophylaxis in 97% unnecessarily and expose the women on human product, with all risk of it. Also, there is a possibility to save a stock of RhD-negative blood in these women, if the transfusion is necessary.
Some of the metrics are blocked by your
consent settings
Case report for management of pregnancy and delivery in severe factor XII deficiency
(БАПОН, 2023)
Dejanova-Ilievska Violeta
;
Makarovska Bojadjieva Tatjana
;
;
;
Ristovska Elena
Factor XII deficiency is rare bleeding disorder and theoretically may carry either bleeding risk as a result of reduced coagulation factors or thrombosis risk as a consequence of reduced fibrinolytic activity. The incidence of factor XII deficiency is relatively low at 1 in 1,000,000 people. The aim of reported case is to emphasise the importance of multidisciplinary approach in the management of pregnancy and delivery in the women with severe factor XII deficiency. A woman with severe factor XII deficiency was successfully treated during her two pregnancies and deliveries. All coagulation tests were performed with standard Siemens reagents on the coagulometer Dade Behring BCS XP. A test for platelet aggregation for follow up of Aspirin treatment was performed on Siemens Innovance PFA-200 with standard Siemens collagen/epinephrin test cartridge. During her two pregnancies, the woman with severe factor XII deficiency was regularly followed up in the Center for haemophilia in the Institute for Transfusion Medicine. According to coagulation tests in the first pregnancy she was treated with low molecular weight heparin in the postpartum period, but in the second pregnancy it was necessary to be treated in the first and third trimester, as well as in the postpartum period. Bleeding prevention due to delivery was performed with tranexamic acid. Two pregnancies were successfully finished with vaginal delivery without any bleeding or thrombotic complications. Regular follow up during pregnancy is necessary for women with bleeding disorders in Comprehensive Haemophilia Treatment Centre. Multidisciplinary approach is crucial for successful bleeding disorders care
Some of the metrics are blocked by your
consent settings
Multidisciplinary approach to management of hypofibrinogenemia in pregnancy: a case report
(Društvo doktora medicine Republike Srpske, Banja Luka i Univerzitet u Banjoj Luci - Medicinski fakultet, Banja Luka, 2020-06-30)
;
Elizabeta Todorovska
;
Tatjana Makarovska Bojadjieva
;
;
Saso Stojcevski
Inherited fibrinogen disorders introduce risk for recurrent abortions, sub-chorionic haematoma, placental abruption and postpartum haemorrhage. This is a case report of a successful pregnancy outcome in a 37-year old woman with hypofibrinogenaemia. She was referred to a coagulation test in the first trimester because of history of preeclampsia and HELLP syndrome in previous pregnancy. Hypofibrinogenaemia was diagnosed with fibrinogen level of 0.7 g/L. During the pregnancy she was regularly monitored for fibrinogen levels and multiple cryoprecipitate concentrates were given. She delivered at 39th gestation week, with elective caesarean section under general anaesthesia. There was one episode of postpartum haemorrhage treated with 2 units of red blood cells, repeated infusions of cryoprecipitate to obtain the level of fibrinogen of 2 g/L. She was discharged on the 6th postpartum day in a good condition. In these disorders levels of fibrinogen should be higher than 1 g/L during pregnancy or 2 g/L in case of caesarean section for successful prenatal and peripartal management.
Some of the metrics are blocked by your
consent settings
EVALUATION OF TOTAL BLOOD LOSS AFTER ADMINISTRATION OF TRANEXAIMC ACID IN TOTAL HIP ARTHROPLASTY
(MIT University Skopje, 2025-03)
;
;
;
;
Total arthroplasty is one of the most frequent procedures in orthopedic surgery, proven to be an effective treatment that significantly improves patients' quality of life. However, it is associated with considerable perioperative blood loss which can lead to suboptimal outcomes and systemic complications. The aim of this study is to assess the total blood loss after the application of tranexamic acid in patients undergoing total hip arthroplasty surgery. A total of 64 patients were included, divided into two groups: a test group where tranexamic acid was administered intravenously and a control group where tranexamic acid was not used. The values for total blood loss and erythrocyte volume loss were statistically significantly lower in the test group. Blood loss in the control group was higher by an average of 482.19 ml. Erythrocyte loss in the control group was higher by an average of 256.28 ml. The use of tranexamic acid as a standard protocol in total hip arthroplasty is a safe and effective method to reduce total blood loss. Ultimately, this results in a reduced need for blood transfusion, a decrease in potential risks and complications associated with it, and the achievement of pharmacoeconomic benefits.
Some of the metrics are blocked by your
consent settings
THE ROLE OF ABO BLOOD GROUP SYSTEM IN THE OCCURRENCE OF VENOUS THROMBOEMBOLISM
(Македонско здружение по кардиологија, 2024-12)
;
;
;
;
Dejanova Ilievska, Violeta
Abstract Background. The association of blood group antigens, especially those from the ABO system and some diseases is well known. The alleles of the ABO locus have functional effect on the level of some plasma coagulation factors which contributes to a thrombophilic condition and increase the risk for occurrence of venous thromboembolism. Aim. To examine relationship between ABO blood genotype with the occurrence of thromboembolic disease in our population, as well as to asses the risk for thrombosis in individuals with non-OO blood group genotype in comparison to those who poses it. Material and methods. This prospective case control study included 52 patients with a confirmed diagnosis of venous thromboembolism (VTE) and a control group of 50 healthy subjects who do not have a personаl or family history of thrombosis. The tests wеre performed on a sample of venous blood 2-6 ml in EDTA, in the laboratories of the Institute of transfusion medicine in R.N. Macedonia. In addition to the serological ABO typing, ABO aleles from ABO system (A1, A2, O1, O2, B) were determined by molecular methods (PCR-SSP and RT-PCR). Results. The results from ABO phenotyping and ABO genotyping performed in patients with VTE, as well as in the control group, show significant correlation with non-OO genotypes and occurrence of VTE in our population, in manner of increased additional trombotic risk, as a result of ABO system. Patients with VTE with non-OO genotype are with significant higher prevalence with 86.5%, in comparison with 13.5% occurrence of OO genotypes (x2 test p=0,027 (p<0.05)). The most frequent genotype in group of patients with VTE is O1A1 with 40.4%, while in control group is O1O1 with 32% occurrence. The genotype O1A1 is most frequent genotype in three groups of patients with VTE, in group of patients with deep vein thrombosis (DVT), pulmonary embolism (PE) and in those where is diagnosed DVT and PE in the same time, with occurrence of 35.7%, 55.5% and 50% respectively, but with significant lower occurrence of this genotype in control group with 24%. Genotype A1A1 has statistically significant correlation with occurrence of PE in our population. In correlation with occurrence of DVT are O1A1 and O1B genotypes and in correlation with PE is O1A1 genotype. Conclusion. The results confirm association on ABO blood group system with the occurrence of venous thromboembolism, so non-OO genotypes are connected with higher trombotic risk in comparison with OO genotypes in population in R.N. Macedonia.

Petkovikj, Elena

Filters

Settings

Sort By

Results per page